Currently, there are a number of treatments for wet age-related macular degeneration, including the drugs Lucentis, Eylea, and Avastin, administered by injection with a very small needle directly into the eye after the surface has been numbed (also called “intra-vitreous injection”). There are also a number of treatments that have proven to be inconclusive or … Continued
Although the advent of anti-VEGF therapy (explained below), administered via eye injection with Lucentis, Eylea, or Avastin, has revolutionized the treatment (but not cure) of wet age-related macular degeneration (AMD), there remain a number of challenges associated with treatment, including the need for appropriate emotional support and development of effective coping strategies. A new study … Continued
Of all the eye research developments reported on the VisionAware blog, it is stem cell research for eye disease that generates the most inquiries from our readers. Many readers request information about stem cells, assuming that this is an established and widely-performed treatment for eye disease; others ask for help in finding a doctor who … Continued
At present, there are a number of current treatments for wet age-related macular degeneration, including the drugs Lucentis, Eylea, and Avastin, administered by injection with a very small needle directly into the eye after the surface has been numbed. There have also been a number of treatments that have proven to be inconclusive or unsuccessful … Continued
Many readers have been following closely the development of Squalamine Eye Drops for wet age-related macular degeneration, hoping that a self-administered at-home eye drop could reduce, or even eliminate, the need for monthly or as-needed eye injections. Unfortunately, a clinical trial designed to test this concept has produced disappointing results: Squalamine Eye Drops failed to … Continued
Although the advent of anti-VEGF therapy (explained below), administered via eye injection with Lucentis, Eylea, or Avastin, has revolutionized the treatment of wet age-related macular degeneration (AMD), there are still a number of persons who do not respond to treatment. It is these “non-responders” or “reduced responders” who continue to pose significant challenges to doctors … Continued
Although the injectable drugs Lucentis, Eylea, or Avastin have revolutionized the treatment of wet macular degeneration and diabetic eye disease, questions persist among persons with these eye disorders about the safety and tolerability of the eye injection procedures themselves: “How painful are they?” and “Are they safe? What are the chances that I’ll get a … Continued
Although the advent of anti-VEGF therapy (also called eye injections, explained below) has revolutionized the treatment of wet age-related macular degeneration (AMD), there are still a number of persons – although in the minority – who do not respond to treatment. It is these “non-responders” or “reduced responders” who continue to pose significant challenges to … Continued
Please note: This is an older post and there have been setbacks and significant changes in stem cell research for eye disease since this was first published. For more current information, see Our Readers Want to Know: What Is the Progress of Stem Cell Research for Eye Disease? Answer: It Has a Very Long Way … Continued
Although there have been a number of significant advances in the treatment of diabetic eye disease, including Avastin, Lucentis, and Eylea injections, this approach has not proven to be effective in preventing the development of diabetic eye disease and proliferative diabetic retinopathy (explained below). Recently, however, a research group from the United States and China … Continued